Alembic Pharmaceuticals financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹2,150cr+25.7% on Q1 FY26
Net profit
₹172cr+12.2% on Q1 FY26
EBITDA margin
15.4%−1.0 pts on Q1 FY26
EPS
₹8.80+12.1% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue2,1501,711+25.7%
EBITDA332281+18.0%
EBITDA margin15.4%16.5%−1.0 pts
Profit before tax221191+16.2%
Net profit172154+12.2%
EPS₹8.80₹7.85+12.1%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹2,150 crNet profit₹172 crNet margin8.0%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
15,386————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
19619683.512075.5
−5.8−5.8−1.40.00.0
1,3611,3611,196430636
16,545————
7,7847,3456,6726,2295,653
—+10.1%+7.1%+10.2%—
1,1691,1181,008933708
15.0%15.2%15.1%15.0%12.5%
826800730661433
690671582616342
8.9%9.1%8.7%9.9%6.1%
₹35.16₹34.33₹29.68₹31.33₹17.40
—+15.7%−5.3%+80.1%—
—78388.0803724
—−435−564−327−443
348348−476476281
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

APLLTD₹782.80

Alembic Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersAJANTPHARMIPCALABTORNTPHARMALIVUSAKUMSAGARWALEYEADVENZYMESAARTIPHARMMcap ₹15,386 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————15,385.9
- Cash, Equiv & ST Investments75.5120.283.5196.4196.4
+ Minority Interest0.00.0-1.4-5.8-5.8
+ Total Debt635.9430.51,195.61,360.91,360.9
Enterprise Value————16,544.6
Revenue5,652.66,228.66,672.17,344.97,784.0
Growth %, YoY—+10.2+7.1+10.1—
EBITDA708.4933.41,008.21,118.51,169.0
Margin %12.5314.9815.1115.2315.02
EBIT432.9660.7729.7799.9826.5
Net Income342.0615.8582.0670.8689.6
Margin %6.059.898.729.138.86
EPS, Adj (current shares)17.4031.3329.6834.3335.16
Growth %, YoY—+80.1-5.3+15.7—
Cash from Operations723.9803.288.0782.7—
Capital Expenditures-443.4-327.5-563.6-434.6—
Free Cash Flow280.5475.7-475.7348.1348.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Alembic Pharmaceuticals financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Alembic Pharmaceuticals (NSE: APLLTD) had a market capitalisation of ₹15,623 crore at the 29 October 2026 close (₹794.85 a share), a PE ratio of 22.6 on the last four quarters' profit and a price-to-book ratio of 2.75. In FY26 its consolidated net profit attributable to shareholders was ₹675 crore on revenue of ₹7,345 crore; in Q1 FY27 (April–June 2026) it was ₹173 crore, up 12.1% year on year. Its debt-to-equity ratio was 0.24 on 31 March 2026. Promoters held 69.87% of the shares on 30 September 2026.

Share price used
₹794.85 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Alembic Pharmaceuticals at a glance · consolidated

Market cap
₹15,623 Crat ₹794.85 · 29 Oct close
PE ratio (last 4 quarters)
22.623.2 on FY26 profit
Price to book (PB)
2.75book value ₹288.72 a share
ROE (FY26)
12.4%+0.8 pts vs FY25ROCE 13.9%
Debt to equity
0.24net debt ₹1,158 Cr
Promoter holding
69.87%unchanged vs 30 Jun 202630 September 2026
Dividend yield
1.51%₹12 a share in 12 months
Net worth
₹5,675 Cr+9.3% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹348 Cr

Questions

What is the Alembic Pharmaceuticals PE ratio today?

Alembic Pharmaceuticals' PE ratio is 22.6 at the 29 October 2026 close (₹794.85 a share): a market capitalisation of ₹15,623 crore divided by consolidated net profit attributable to shareholders of ₹692 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹675 crore) it is 23.2.

What is the Alembic Pharmaceuticals PB ratio (price to book value)?

Alembic Pharmaceuticals' price-to-book (PB) ratio is 2.75 at the 29 October 2026 close: a market capitalisation of ₹15,623 crore divided by shareholders' equity (book value) of ₹5,675 crore on 31 March 2026. That is a book value of ₹288.72 per share against a share price of ₹794.85.

What is the Alembic Pharmaceuticals ROE and ROCE?

In FY26, Alembic Pharmaceuticals' return on equity (ROE) was 12.4% and its return on capital employed (ROCE) was 13.9%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 11.7% and ROCE 14.1%.

What is the Alembic Pharmaceuticals market cap?

Alembic Pharmaceuticals' market capitalisation was ₹15,623 crore at the 29 October 2026 close: 19.66 crore shares at ₹794.85 each.

Is Alembic Pharmaceuticals debt free?

No. Alembic Pharmaceuticals had borrowings of ₹1,361 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.24. Its cash and current investments were ₹203 crore, so its net debt was ₹1,158 crore.

What is the Alembic Pharmaceuticals EPS?

Alembic Pharmaceuticals' basic earnings per share (EPS) were ₹34.33 in FY26, against ₹29.68 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹35.27.

What is the Alembic Pharmaceuticals debt to equity ratio?

Alembic Pharmaceuticals' debt-to-equity ratio was 0.24 on 31 March 2026: borrowings of ₹1,361 crore against total equity of ₹5,669 crore. A year earlier, on 31 March 2025, it was 0.23.

What is the Alembic Pharmaceuticals net worth?

Alembic Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹5,675 crore on 31 March 2026, up 9.3% from ₹5,191 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹15,623 crore at the 29 October 2026 close.

What is the Alembic Pharmaceuticals promoter holding?

Promoters held 69.87% of Alembic Pharmaceuticals on 30 September 2026, unchanged from the previous quarter and up 0.13 percentage points from 69.74% a year earlier, according to the shareholding pattern filed with NSE.

What is the Alembic Pharmaceuticals book value per share?

Alembic Pharmaceuticals' book value per share was ₹288.72 on 31 March 2026: shareholders' equity of ₹5,675 crore divided by the 19.66 crore shares in issue, up 9.3% from ₹264.10 a year earlier. The share price at the 29 October 2026 close was ₹794.85.

What is the Alembic Pharmaceuticals dividend yield?

Alembic Pharmaceuticals' dividend yield is 1.51% at the 29 October 2026 close: dividends of ₹12 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹794.85. They were ₹12 on 29 July 2026.

What is the Alembic Pharmaceuticals free cash flow?

In FY26, Alembic Pharmaceuticals generated ₹783 crore of cash from operations and spent ₹435 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹348 crore. In FY25 it was −₹476 crore.

What is the Alembic Pharmaceuticals dividend in 2026 and its record date?

In 2026, Alembic Pharmaceuticals has declared one dividend: ₹12 with record date 29 July 2026.

What are the Alembic Pharmaceuticals latest quarterly results?

Alembic Pharmaceuticals' latest results are for Q1 FY27 (April–June 2026), filed on 4 August 2026: consolidated net profit attributable to shareholders ₹173 crore, up 12.1% from ₹154 crore in Q1 FY26; revenue from operations ₹2,150 crore, up 25.7% year on year.

When are the Alembic Pharmaceuticals next results?

Alembic Pharmaceuticals will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, the date of the board meeting it has notified to the exchanges.

What is the Alembic Pharmaceuticals shareholding pattern?

On 30 September 2026, Alembic Pharmaceuticals' shares were held by promoters 69.87%, foreign portfolio investors (FII/FPI) 4.55%, domestic institutions (DII) 15.43% (including mutual funds at 8.50%) and retail and other non-institutional investors 10.15%. Over the year, FII holding was up 0.50 percentage points from 4.05% and DII holding was down 0.87 percentage points from 16.30%.

What is the Alembic Pharmaceuticals revenue and profit in FY26?

In FY26 (April 2025–March 2026), Alembic Pharmaceuticals' consolidated net profit attributable to shareholders was ₹675 crore, up 15.7% from ₹583 crore in FY25, on revenue from operations of ₹7,345 crore (up 10.1%). Over three years, from FY23, net profit was up 97.3%.

How does the Alembic Pharmaceuticals PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Alembic Pharmaceuticals' PE ratio is 23.2, the lowest of the four: Ajanta Pharmaceuticals 41.1, Ipca Laboratories 42.8 and Torrent Pharma 80.5, a peer average of 54.8. Each is the company's market capitalisation at that price divided by its FY26 net profit.

How does Alembic Pharmaceuticals compare with its peers?

On FY26 consolidated figures, against Ajanta Pharmaceuticals, Ipca Laboratories and Torrent Pharma: Alembic Pharmaceuticals' operating margin of 10.9% is the lowest of the four (Ajanta Pharmaceuticals 22.4%, Ipca Laboratories 16.2%, Torrent Pharma 24.6%; peer average 21.1%); its return on equity of 12.4% is the lowest of the four (Ajanta Pharmaceuticals 25.4%, Ipca Laboratories 15.2%, Torrent Pharma 27.1%; peer average 22.6%); its revenue growth over three years of 9.1% a year is the lowest of the four (Ajanta Pharmaceuticals 13.4% a year, Ipca Laboratories 15.6% a year, Torrent Pharma 13.3% a year; peer average 14.1% a year).

Alembic Pharmaceuticals vs Ajanta Pharmaceuticals: how do they compare?

In FY26, Alembic Pharmaceuticals earned net profit attributable to shareholders of ₹675 crore on revenue of ₹7,345 crore, against ₹1,056 crore on ₹5,453 crore for Ajanta Pharmaceuticals. Alembic Pharmaceuticals' operating margin was 10.9% (Ajanta Pharmaceuticals 22.4%) and its return on equity 12.4% (Ajanta Pharmaceuticals 25.4%). At the 29 October 2026 close, Alembic Pharmaceuticals' market capitalisation was ₹15,623 crore against ₹43,367 crore for Ajanta Pharmaceuticals, and its PE ratio on FY26 profit 23.2 against 41.1.

Where do these Alembic Pharmaceuticals figures come from?

From Alembic Pharmaceuticals' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.